VIGL (Vigil Neuroscience) Cash, Cash Equivalents, Marketable Securities : $87.10 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience Cash, Cash Equivalents, Marketable Securities?

Vigil Neuroscience's quarterly cash, cash equivalents, marketable securities declined from Sep. 2024 ($111.27 Mil) to Dec. 2024 ($97.80 Mil) but then stayed the same from Dec. 2024 ($97.80 Mil) to Mar. 2025 ($87.10 Mil).

Vigil Neuroscience's annual cash, cash equivalents, marketable securities declined from Dec. 2022 ($186.61 Mil) to Dec. 2023 ($117.94 Mil) and declined from Dec. 2023 ($117.94 Mil) to Dec. 2024 ($97.80 Mil).

Vigil Neuroscience Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Vigil Neuroscience's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vigil Neuroscience Cash, Cash Equivalents, Marketable Securities Chart

Vigil Neuroscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash, Cash Equivalents, Marketable Securities

24.15

91.42

186.61

117.94

97.80

Vigil Neuroscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial														101.65	86.67	111.27	97.80	87.10

Vigil Neuroscience Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Vigil Neuroscience (NAS:VIGL) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Vigil Neuroscience Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vigil Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Forge Road, Suite 700, Watertown, MA, USA, 02472

Website

https://www.vigilneuro.com

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

Executives

Ivana Magovcevic-liebisch	director, officer: President and CEO	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Budd Haeberlein Samantha L.	director	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Christopher Silber	officer: Chief Medical Officer	C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F.	officer: Chief Science Officer	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos	officer: Chief Medical Officer	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry	officer: SVP, Head of Early Development	VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski	officer: Chief Financial Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni	officer: General Counsel	VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Atlas Venture Fund Xii, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814